- Category: HCV Treatment
- Published on Thursday, 26 May 2016 00:00
- Written by Michael Carter
New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection. Results from the C-EDGE Head-to-Head study were presented at the recent EASL International Liver Congress in Barcelona.